参考文献/References:
[1] Hundahl SA, Fleming ID, Fremgen AM, et al.A National cancer data base report on 53, 856 cases of thyroid carcinoma treated in the U.S.,1985-1995[J].J Cancer, 1998, 83(12):2638-2648.
[2] 杨雷, 郑荣寿, 王宁, 等.2010年中国甲状腺癌发病和死亡情况[J].中华预防医学杂志, 2014, 48(8):663-668.DOI:10.3760/cma.j.issn.0253-9624.2014.08.003.Yang L, Zheng RS, Wang N, et al.Analysis of incidence and mortality of thyroid cancer in China[J].Chin J Prev Med, 2014, 48(8):663-668.
[3] Sosa JA, Hanna JW, Robinson KA, et al.Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States[J].Surgery, 2013, 154(6):1420-1427.DOI:10.1016/j.surg.2013.07.006.
[4] Li N, Du XL, Reitzel LR, et al.Impact of enhanced detection on the increase in thyroid cancer incidence in the United States:review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980-2008[J].Thyroid, 2013, 23(1):103-110.DOI:10.1089/thy.2012.0392.
[5] Rivera M, Ghossein RA, Schoder H, et al.Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma[J].Cancer, 2008, 113(1):48-56.DOI:10.1002/cncr.23515.
[6] Durante C, Haddy N, Baudin E, et al.Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma:Benefits and limits of radioiodine therapy[J].J Clin Endocrinol Metab, 2006, 91(8):2892-2899.DOI:10.1210/jc.2005-2838.
[7] Xing MZ.Molecular pathogenesis and mechanisms of thyroid cancer[J].Nat Rev Cancer, 2013, 13(3):184-199.DOI:10.1038/nrc3431.
[8] Cancer Genome Atlas Research Network.Integrated genomic characterization of papillary thyroid carcinoma[J].Cell, 2014, 159(3):676-690.DOI:10.1016/j.cell.2014.09.050.
[9] Elisei R, Ugolini C, Viola D, et al.BRAFV600E mutation and outcome of patients with papillary thyroid carcinoma:a 15-year median follow-up study[J].J Clin Endocrinol Metab, 2008, 93(10):3943-3949.DOI:10.1210/jc.2008-0607.
[10] Hou P, Liu D, Xing M.Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer[J].Cell Cycle, 2007, 6(3):377-379.
[11] O’neill CJ, Bullock M, Chou A, et al.BRAFV600E mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer[J].Surgery, 2010, 148(6):1139-1146.DOI:10.1016/j.surg.2010.09.005.
[12] Kebebew E, Weng J, Bauer J, et al.The prevalence and prognostic value of BRAF mutation in thyroid cancer[J].Ann Surg, 2007, 246(3):466-471.DOI:10.1097/SLA.0b013e318148563d.
[13] Durante C, Puxeddu E, Ferretti E, et al.BRAF mutations in papillary thyroid carcinomas inhibit genes involved in Iodine metabolism[J].J Clin Endocrinol Metab, 2007, 92(7):2840-2843.DOI:10.1210/jc.2006-2707.
[14] Xing M.BRAF mutation in papillary thyroid cancer:pathogenic role, molecular bases, and clinical implications[J].Endocr Rev, 2007, 28(7):742-762.DOI:10.1210/er.2007-0007.
[15] Zhu Z, Ciampi R, Nikiforova MN, et al.Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas:effects of the detection methods and genetic heterogeneity[J].J Clin Endocrinol Metab, 2006, 91(9):3603-3610.DOI:10.1210/jc.2006-1006.
[16] Santoro M, Carlomagno F, Hay ID, et al.Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype[J].J Clin Invest, 1992, 89(5):1517-1522.DOI:10.1172/JCI115743.
[17] Trapasso F, Iuliano R, Chiefari E, et al.Iodide symporter gene expression in normal and transformed rat thyroid cells[J].Eur J Endocrinol, 1999, 140(5):447-451.
[18] Schlumberger M, Brose M, Elisei R, et al.Definition and management of radioactive iodine-refractory differentiated thyroid cancer[J].Lancet Diabetes Endocrinol, 2014, 2(5):356-358.DOI:10.1016/S2213-8587(13)70215-8.
[19] Wilhelm SM, Carter C, Tang L, et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Res, 2004, 64(19):7099-7109.DOI:10.1158/0008-5472.CAN-04-1443.
[20] Thomas L, Lai SY, Dong W, et al.Sorafenib in metastatic thyroid cancer:a systematic review[J].Oncologist, 2014, 19(3):251-258.DOI:10.1634/theoncologist.2013-0362.
[21] Brose MS, Nutting CM, Jarzab BA, et al.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer:a randomised, double-blind, phase 3 trial[J].Lancet, 2014, 384(9940):319-328.DOI:10.1016/S0140-6736(14)60421-9.
[22] White PT, Cohen MS.The discovery and development of sorafenib for the treatment of thyroid cancer[J].Expert Opin Drug Discov, 2015, 10(4):427-439.DOI:10.1517/17460441.2015.1006194.
[23] Walko CM, Grande C.Management of common adverse events in patients treated with sorafenib:nurse and pharmacist perspective[J].Semin Oncol, 2014, 41(Suppl 2):S17-28.DOI:10.1053/j.seminoncol.2014.01.002.
[24] Dadu R, Devine C, Hernandez M, et al.Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib[J].J Clin Endocrinol Metab, 2014, 99(6):2086-2094.DOI:10.1210/jc.2013-3588.
[25] Wells SA Jr, Robinson BG, Gagel RF, et al.Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer:a randomized, Double-Blind phase Ⅲ trial[J].J Clin Oncol, 2012, 30(2):134-141.DOI:10.1200/JCO.2011.35.5040.
[26] Cabanillas ME, Schlumberger M, Jarzab B, et al.A phase 2 trial of lenvatinib(E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer:A clinical outcomes and biomarker assessment[J].Cancer, 2015, 121(16):2749-2756.DOI:10.1002/cncr.29395.
[27] Schlumberger M, Tahara M, Wirth LJ, et al.Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J].N Engl J Med, 2015, 372(7):621-630.DOI:10.1056/NEJMoa1406470.
[28] Carr LL, Mankoff DA, Goulart BH, et al.Phase Ⅱ study of daily sunitinib in FDG-PET-Positive, Iodine-Refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation[J].Clin Cancer Res, 2010, 16(21):5260-5268.DOI:10.1158/1078-0432.CCR-10-0994.
[29] Cohen EE, Rosen LS, Vokes EE, et al.Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer:Results from a phase Ⅱ study[J].J Clin Oncol, 2008, 26(29):4708-4713.DOI:10.1200/JCO.2007.15.9566.
[30] Bible KC, Suman VJ, Molina JR, et al.Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers:results of a phase 2 consortium study[J].Lancet Oncol, 2010, 11(10):962-972.DOI:10.1016/S1470-2045(10)70203-5.
[31] Sherman SI, Wirth LJ, Droz JP, et al.Motesanib diphosphate in progressive differentiated thyroid cancer[J].N Engl J Med, 2008, 359(1):31-42.DOI:10.1056/NEJMoa075853.
[32] Cabanillas ME, Brose MS, Holland J, et al.A phase I study of cabozantinib(XL184) in patients with differentiated thyroid cancer[J].Thyroid, 2014, 24(10):1508-1514.DOI:10.1089/thy.2014.0125.
[33] Sherman SI.Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers[J].J Clin Endocrinol Metab, 2009, 94(5):1493-1499.DOI:10.1210/jc.2008-0923.
[34] Kim KB, Cabanillas ME, Lazar AJ, et al.Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAFV600E mutation[J].Thyroid, 2013, 23(10):1277-1283.DOI:10.1089/thy.2013.0057.
[35] Brose MS, Cabanillas ME, Cohen E, et al.An open-label, multi-center phase 2 study of the BRAF inhibitor vemurafenib in patients with metastatic or unresectable papillary thyroid cancer(PTC) positive for the BRAFV600 mutation and resistant to radioactive Iodine(NCT01286753, NO25530)[J].Eur J Cancer, 2013, 49(3):S13.
[36] Dadu R, Shah K, Busaidy NL, et al.Efficacy and tolerability of vemurafenib in patients with BRAFV600E-positive papillary thyroid cancer:M.D.Anderson Cancer Center off label experience[J].J Clin Endocrinol Metab, 2015, 100(1):E77-E81.DOI:10.1210/jc.2014-2246.
[37] Falchook GS, Millward M, Hong D, et al.BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer[J].Thyroid, 2015, 25(1):71-77.DOI:10.1089/thy.2014.0123.
[38] Lorch JH, Busaidy N, Ruan DT, et al.A phase Ⅱ study of everolimus in patients with aggressive RAI refractory(RAIR)thyroid cancer(TC)[J/OL].J Clin Oncol, 2013, 31(15):6023[2015-11-18].http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/6023.
[39] Lim SM, Chang H, Yoon MJ, et al.A multicenter, phase Ⅱ trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes[J].Ann Oncol, 2013, 24(12):3089-3094.DOI:10.1093/annonc/mdt379.
相似文献/References:
[1]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[2]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[3]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[4]刘斌,潘明志.BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展[J].国际放射医学核医学杂志,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
Liu Bin,Pan Mingzhi.Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
[5]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
[6]刘鹏杰,唐铭,邓智勇,等.131I治疗儿童分化型甲状腺癌期间出现低钙血症伴癫痫发作一例[J].国际放射医学核医学杂志,2015,39(4):352.[doi:10.3760/cma.j.issn.1673-4114.2015.04.017]
[7]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[8]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[9]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
[10]李莉,晋建华,陆克义,等.131I去除分化型甲状腺癌术后残留甲状腺组织疗效的meta分析[J].国际放射医学核医学杂志,2014,38(3):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
Li Li,Jin Jianhua,Lu Keyi,et al.A meta-analysis of efficacy of iodine-131 for post-thyroidectomy ablation of remnants in patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]